87: Severe Multiple Sclerosis and the CASA-MS Study

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Robert Zivadinov, MD, PhD, director of the Buffalo Neuroimaging Analysis Center, and a professor of neurology and biomedical informatics at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo. He discussed the recent CASA-MS study that he and colleagues conducted into a subgroup of patients with multiple sclerosis (MS) who develop rapid and progressive disability at a relatively young age, which he presented earlier this year at the 2023 Americas Committee for Treatment and Research in MS Forum, and the critical effectively need to treat this group of patients. The study was carried out at The Boston Home, a specialized residential facility for individuals with advanced progressive neurological disorders, in Dorchester, Massachusetts, and at the University at Buffalo, in New York. Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page. Episode Breakdown: 1:10 – Background on the CASA-MS study subpopulation 3:45 – Topline results of the study 6:05 – The need for further clarification in MS populations 7:10 – The utility of biomarkers such as GFAP 12:15 – Further assessment plans for the CASA-MS cohort 14:15 – Neurology News Minute 18:35 – Access to the tools to characterize progressive MS 21:30 – The potential with portable MRI and artificial intelligence 25:25 – Unmet needs in progressive MS This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Phase 3 Study of GTX-104 in Subarachnoid Hemorrhage Expected to Proceed Following FDA Feedback FDA Places Partial Hold on Evobrutinib Initiation in Newly Enrolled Patients With MS FDA Panel Votes in Favor of Brexpiprazole as Potential Therapy for Alzheimer Agitation FDA Approves IntelGenx and Gensco's Rizatriptan for Acute Migraine Treatment DEA Rules Fenfluramine No Longer a Controlled Substance Atogepant’s Indication Expanded to Include Prevention of Chronic Migraine FDA Grants Breakthrough Device Designation to Reach Neuro’s Chronic Stroke Platform FDA Approves CSL Behring's Immune Globulin Subcutaneous Prefilled Syringe for PI and CIDP Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE 1. Zivadinov R, Jakimovski D, Burnham A, et al. Comprehensive Assessment of Severely Affected Multiple Sclerosis (CASA-MS) Study. Presented at: ACTRIMS Forum; February 25-28, 2023; San Diego, CA. P430. www.abstractsonline.com/pp8/#!/10822/presentation/468